Give someone a chance to live by joining the stem cell registry | Daily News – Independent Online

Durban - Every year individuals around the world are diagnosed with leukaemia and other life-threatening blood diseases.

For many, their only hope of a cure is a life-saving blood stem cell transplant. This is why the Sunflower Fund will be embarking on a blood stem cell donor drive which will be held on Tuesday to recruit donors onto their registry.

At least 75% of stem cell patients are under the age of 25 years, this is according to The Sunflower Fund - a scary fact and anyone is at risk of being diagnosed with a blood disease.

The Sunflower Fund spokesperson Xolani Hlongwane says that interested donors need to be between 18-45 and willing to help anyone.

Donors also need to weigh the constant weight of 50 and above, no chronic illnesses, no heart, brain or back surgery., he said.

See the rest here:
Give someone a chance to live by joining the stem cell registry | Daily News - Independent Online

Health: Botanix buddy set to benefit after DEA admits their synthetic CBD is probably ok – Stockhead

Following last months disastrous news that a cannabidiol (CBD) acne trial failed, Botanix (ASX:BOT) may win back doubters after convincing the DEA to de-schedule synthetic CBD.

The Drug Enforcement Agency (DEA) has removed the synthetic CBD made by Georgia-based Purisys from its druge schedule, and told the two companies on Friday it would no longer be scheduled as a controlled substance at all, because it could prove it effectively contains no THC.

Before now companies using synthetic or natural CBD needed licences from the DEA for all aspects of logistics and use, and cross-border transport was tightly controlled.

Stockhead understands this change is only for Purisys and is not an industry-wide shift in position from the DEA.

The company says the change will greatly reduce its costs.

The US drug law enforcer moved in late 2018 to re-schedule CBD generally from category 1 (in with cocaine and heroin) to category 5, meaning it considers the substance to have some medical benefit but is open to abuse.

Botanix signed with Purisys in October to supply all of the synthetic CBD it needs.

Also in October, Botanix said its acne trial failed: the 368 patient trial of BTX 1503 only worked for 40 per cent of cases, which isnt better than current non-CBD drugs on the market.

To be commercialised, drugs have to be better, not just the same.

Kazia Therapeutics (ASX:KZA) may be able to give glioblastoma (brain cancer) sufferers three more months of life with its drug, but cant be completely sure yet because thats based on data from the first eight patients with viable data, in a 29-patient phase two clinical trial. They do not yet have an overall survival rate.

Cynata (ASX:CYN) has applied for permission to start a phase two trial on critical limb ischaemia, a disease that involves the narrowing of arteries in the limbs. It generally results in amputations and is a risk factor for heart attacks. The company wants to test its Cymerus mesenchymel stem cell treatment on it.

Go here to read the rest:
Health: Botanix buddy set to benefit after DEA admits their synthetic CBD is probably ok - Stockhead

Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief – PR Web

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says.

MILWAUKEE (PRWEB) November 25, 2019

The American Society of Gene & Cell Therapy (ASGCT) announced today the appointment of Roland W. Herzog, Ph.D. and Gerhard Bauer as editors-in-chief of the Societys field-leading journals, Molecular Therapy and Molecular TherapyMethods & Clinical Development, respectively. Both editors will begin their positions effective January 1, 2020.

Herzog, currently the editor-in-chief of Molecular TherapyMethods & Clinical Development, will assume the same role for a five-year term at Molecular Therapy from Seppo Yl-Herttuala, M.D., Ph.D. at the conclusion of Yl-Herttualas term. Herzog is also a professor of pediatrics, Riley Children's Foundation Professor of Immunology, and director of the gene and cell therapy program at Indiana University.

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says. My vision has continued and even further strengthened close coordination and collaboration between the journal editors and partnership with Cell Press and ASGCT.

Bauer replaces Herzog at the helm of Molecular TherapyMethods & Clinical Development after serving as an associate editor of the same journal for more than four years. Bauer is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures.

Over the years that I have been looking at manuscripts submitted to the journal, I have always loved the articles dealing with translational research, getting the products ready for clinical applications, improving their utility and solving problems in the manufacturing of these products, Bauer says. Now, at a time where we have clinical efficacy and also commercially approved cell and gene therapy products that save lives, it is even more important to strengthen the translational research field.

ASGCTs official journal, Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2018 impact factor is 8.402.

The aim of Molecular TherapyMethods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular TherapyMethods & Clinical Development's 2018 impact factor is 4.875.

In addition to Molecular Therapy and Molecular Therapy Methods & Clinical Development, ASGCT also owns and operates two other sibling journals, Molecular TherapyNucleic Acids (2018 impact factor 5.919) and Molecular TherapyOncolytics (2018 impact factor 5.710).

About ASGCTThe American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Share article on social media or email:

Read more here:
Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief - PR Web

Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,…

In the forecast period, the global stem cell therapy market is expected to generate revenue about 978 million USD in 2027, growing at a CAGR of 20% by 2019-2027.

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem Cell Therapy Market are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells.

Report Consultant has added a new report to its database that qualifies an expressive and professional look into this market. The report is titled a Global stem cell therapy Market. Thus, the report scrutinizes the present-day environment of the market in order to generate a comprehensive understanding of the future plans of the market. Porters five and SWOT analysis have been utilized to scrutinize the Global stem cell therapy Market.

Grab Eye-Popping Black Friday Deals on this Report @

Top Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, and Takeda (TiGenix)

The report provides a brief timeline for each segment of the stem cell therapy market. Key drivers and restraints impacting the market segments are also demonstrated precisely. It also helps in determining reasons for the progress of certain segments over others in the looming years. The overall market is also segmented on the basis of geography in the United States, Europe, India, Japan, China, and Southeast Asia. The geographical segmentation provides a distinct assessment of the factors supporting these regions, the favorable regulatory policies, and the impact of the political frameworks.

The global stem cell therapy market report is integrated considering the primary and secondary research methodologies that have been collected from reliable sources intended to generate a factual database. The data from market journals, publications, conferences, white papers and interviews of key market leaders are compiled to generate our segmentation and is mapped to a fair trajectory of the market during the forecast period.

Get Sample Copy of Report @

https://www.reportconsultant.com/request_sample.php?id=4868

Stem Cell Therapy market On the basis of product,

Stem Cell Therapy market On the basis on the Applications,

In This Study, The Years Considered To Estimate the Size Of stem cell therapy Market Are As Follows:

If you have any special requirements, please let us know and we will offer you the report as you want.

Read more here:
Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,...

Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora – POPSUGAR

Acne is a bummer, whether it shows up on your big day . . . or just a Monday. Chances are you've had to deal with it at some point in your life. (That's why you're reading this, right?) Whether the problem is hormonal, cystic, or something else entirely, it's pretty safe to say no one is excited when they see a new pimple in the mirror.

Now's the time to break up with breakouts for good. Here are top-rated products to add to your clear skin arsenal, straight from Sephora.

You'll find solutions to brighten and treatments to lighten (old scars), not to mention products that exfoliate skin and zap zits. There's even makeup for pimple-prone skin, too.

If you're ready to stage an acne attack (that's an attack on acne, not of acne), find the blemish-blasting products from Sephora that other shoppers are loving ahead.

Originally posted here:
Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora - POPSUGAR

Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in…

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (Celularity ), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, today announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM) in a poster presentation at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix, A.Z.

Results from pre-clinical studies demonstrated in vivo anti-GBM activity of CYNK-001. The positive results from these pre-clinical studies highlight the versatility and activity of our investigational, off-the-shelf, placental-derived NK cell therapy program, said Robert Hariri, M.D., Ph.D., Founder, Chairman and CEO at Celularity. There is a clear need for novel therapeutic approaches to the treatment of glioblastoma multiforme. We look forward to advancing our investigational programs and are optimistic about the possibility of bringing another therapeutic option to patients in need.

About CYNK-001CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. When derived from the placenta, these cells offer intrinsic safety and versatility, allowing potential use across a range of organs and tissues. CYNK-001 is currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and as a potential treatment option for various solid tumors.

About CelularityCelularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases. To learn more, please visit http://www.celularity.com.

Forward-Looking StatementsThis press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

See the rest here:
Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in...

Allogene and the need for a reliable cell source – Vantage

David Chang saw the end goal early. As chief medical officer of Kite Pharma, before that company was ever in allogeneic cell therapy, he did a deal with UCLA to secure a supply of pluripotent stem cells. Now, as chief executive of Allogene, he has repeated the trick, licensing in Notch Therapeutics stem cell technology this month.

Speaking to Vantage at this weeks Jefferies conference in London Mr Chang said that within a month of Allogenes creation he recognised the need to secure cell supply and of course he had done it before, at Kite. Any allogeneic cell therapy company at some point has to start thinking about renewable cell source, he states.

Since the 2017 approvals of Kymriah and Yescarta the development of autologous cell therapy products has stalled, and many investors see allogeneic, or off-the-shelf, therapy as the breakthrough that will move the needle.

However, the first generation of allogeneic players have hit production bottlenecks, and have struggled with cells derived from healthy donors; these tend to be heterogeneous and of variable quality not what is needed when the goal is to produce a reliable, universal product.

Single cell

Using induced pluripotent stem cells (iPSCs) as the source, however, is likened by another player in this field, Fate Therapeutics, to going by monoclonal antibody principles: starting from a single cell line.

The idea is that virtually any adult cell can, in a petri dish, be regressed to an iPSC phenotype, and this, using clever science, can then be reprogrammed into a defined mature cell that can be infinitely expanded.

What the iPSC is differentiated into depends on each developers focus: Allogene is clearly working on T cells, whereas Fate is initially targeting NK cell therapeutics. Each comes with its own degree of difficulty, and Mr Chang argues that differentiating iPSCs into NK cells is possibly easy.

He says Allogene actively went out to source such a technology, and there were several potential partners, though of course the UCLA work was no longer available. Without going into scientific minutiae, the Notch teams underlying concept is the same as that of UCLA, says Mr Chang.

However, the Notch approach is a serum-free, cell-free system to differentiate iPSCs. The UCLA technology, pioneered by Dr Gay Crooks andalso known as an artificial thymic organoid, uses so-called feeder cells on top of which the desired iPSC-derived cells are differentiated.

All that said, the Notch deal caused a degree of consternation, with some Allogene investors seeing it as demonstrating a lack of confidencein Cellectiss donor-derived approach.

Mr Chang says he was taken aback by such pushback, and stresses that the transition from autologous to allogeneic is not a bet on a single technology but a stepwise process. Nevertheless, the clear implication is that, in time, Cellectis's current healthy donor cell source approach will become obsolete.

Though Mr Chang accepts that the science is not quite there to implement the Notch technology into clinical programmes, he says: The way we see the future, whether its five or 10 years down the line, is in the renewable cell source.

Go here to see the original:
Allogene and the need for a reliable cell source - Vantage

Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean – PRNewswire

BEVERLY HILLS, California, Nov. 21, 2019 /PRNewswire/ -- Full Alliance Group, Inc. (OTCPK: FAGI) is pleased to announce the opening of two new EBO2 treatment offices.

Dr. Yu and his staff arrived in Boca Raton, Florida, and then the Cayman Islands earlier this week with two brand-new portable EBO2 units and are currently training Dr. Joseph Purita and his staff. Dr. Purita is well-known in the stem cell and regenerative medicine sector and is eager to implement our ozone technology within his thriving practice.He has offices in Boca Raton as well as in the Cayman Islands.

Dr. Purita's Pensum Regenerative Clinic in Grand Cayman already specializes in stem cell treatment and anti-aging.The addition of EBO2 technology is expected to work synergistically with the well-established stem cell protocols already in place at the clinic.

"Expanding our footprint to the East and South, as well as the Caribbean, has been a critical part of our strategic plan," said Dr. Brian Volpp, MD, CEO and President of Full Alliance Group, Inc. "We are grateful that Dr. Purita has committed to the Yu Method and that he has made the financial commitment for two of our new units.His reputation within the stem cell community should allow ozone therapy to become more mainstream as he gains more experience with integrating EBO2 into his existing protocols."

Also, we have been advised by our legal team that the third quarter financial filing must be made publicly available to all shareholders. Consequently, the filing has been posted on our website:https://FullAlliance.com

About Full Alliance Group Inc.

Full Alliance Group Inc. (OTCPK: FAGI) is a multi-faceted holding company with various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a wholly owned subsidiary of Full Alliance Group, develops, markets, and distributes a proprietary line of nutraceutical products. EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation, ozone exposure and blood filtration.The process filters blood in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply. The EBO2 unit is considered the world's most advanced medical ozone therapy.

For additional information regarding Full Alliance Group, visit, http://www.fullalliance.com.

Paul Brian Volpp, MD, MPH, President / CEO The Full Alliance Group

Forward-Looking StatementsThis shareholder update may contain a number of forward-looking statements. Words and variations of words such as: "expect", "goals", "could", "plans", "believe", "continue", "may", "will", and similar expressions are intended to identify our forward-looking statements, including but not limited to: our expectation for growth, benefits from brand-building, cost savings and margins. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Such factors include, but are not limited to: continued volatility of, and sharp increase in: costs/pricing actions, increased competition, ability to raise sufficient operating capital, risks from operating internationally, consumer weakness, weakness in economic conditions and tax law changes.

Full Alliance Group Inc. Investor RelationsDave DonlinEmail: Info@TheCervelleGroup.comPhone: (407) 490-6635Web: http://www.StockInvestorDaily.comVisit: http://www.fullalliance.comContact: ir@fullalliance.com

SOURCE Full Alliance Group, Inc.

Home

Continue reading here:
Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean - PRNewswire

Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis – Downey Magazine

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Request a PDF Brochure of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

The rest is here:
Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis - Downey Magazine

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -…

CAMBRIDGE, Mass. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCytes Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.

Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCytes Flow Electroporation technology and ExPERT platform to develop up to five engineered cell therapies, including VOR33, Vors lead eHSC candidate, which is in development for acute myeloid leukemia (AML). In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

Vor will use MaxCytes cell engineering platform to deliver its gene editing machinery into hematopoietic stem cells to remove biologically redundant cell surface proteins that are also expressed on blood cancer cells. Once the eHSCs are transplanted into a cancer patient, these cells are effectively hidden from complementary targeted therapies that target the relevant protein, while diseased cells are left vulnerable to attack. Vors approach thereby could unleash the potential of targeted therapies by broadening the therapeutic window and improving the utility of complementary targeted therapies.

MaxCyte is a leader in GMP electroporation technology, and we are thrilled that this agreement provides us with long-term access to a platform technology applicable to a pipeline of eHSC programs used to treat AML and other blood cancers, said Sadik Kassim, Ph.D., Chief Technology Officer of Vor. As we build on promising in vivo data from our lead candidate VOR33, we can now expand our manufacturing capabilities to support later-stage studies, regulatory filings and commercialization of VOR33.

MaxCytes ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

We look forward to expanding our relationship with Vor Biopharma as the company pioneers a potential future standard of care in hematopoietic stem cell transplants for cancer patients in need, said Doug Doerfler, President & CEO of MaxCyte. This agreement represents another key business milestone for MaxCyte, emphasizing the value of our technology platform applied to next-generation engineered cell therapies that may make a true difference in patient outcomes.

About VOR33Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, CD33 becomes a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. In so doing, Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from AML.

About Vor BiopharmaVor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vors lead program has been published in Proceedings of the National Academy of Sciences.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was founded by Dr. Mukherjee and PureTech Health and is supported by leading investors including 5AM Ventures and RA Capital Management, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research and Osage University Partners.

About MaxCyteMaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCytes mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit http://www.maxcyte.com.

See original here:
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -...